EMTN programme: publication of supplement

9 September 2024: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the supplement (the "Supplement") to the base listing particulars (together with the Supplement, the "Base Listing Particulars") dated 3 May 2024 regarding Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s £10,000,000,000 Euro Medium Term Note Programme, guaranteed by the Company, has been published.

A copy of the Supplement, together with the Base Listing Particulars, is available for inspection at and can be downloaded from:

www.haleon.com/investors/debt-investors

Amanda Mellor

Company Secretary

Enquiries

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.  

Disclaimer

Please note that the information contained in the Base Listing Particulars may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Listing Particulars) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Listing Particulars is not addressed.  Prior to relying on the information contained in the Base Listing Particulars, you must ascertain from the Base Listing Particulars whether or not you are part of the intended addressees of the information contained in the Base Listing Particulars.

Your right to access this service is conditional upon complying with the above requirement.